文献速递心脑血管急症消化、代谢与肾脏急症

基因预测睾酮与血栓栓塞、心力衰竭及心肌梗死的关联:UK Biobank 孟德尔随机化研究

Association of genetically predicted testosterone with thromboembolism, heart failure, and myocardial infarction: mendelian randomisation study in UK Biobank.
PubMed 文献 · BMJ · 2019-03-06
一句话结论在男性中,由 JMJD1C 基因区域变异基因预测的内源性睾酮与血栓栓塞和心力衰竭呈正相关,但与心肌梗死无显著关联。

该研究采用两样本孟德尔随机化设计,以遗传变异作为工具变量推断内源性睾酮对血栓栓塞、心力衰竭和心肌梗死的因果作用。数据来自 REDUCE 试验 3225 名欧洲裔男性(50-75 岁)、UK Biobank 392038 名白种英国人(40-69 岁)及 CARDIoGRAMplusC4D 1000 Genomes 研究 171875 名约 77% 欧洲血统参与者(用于验证)。UK Biobank 中分别有 13691 例血栓栓塞、1688 例心力衰竭和 12882 例心肌梗死。在男性中,由 JMJD1C 基因区域变异基因预测的睾酮与血栓栓塞(OR 2.09,95%CI 1.27-3.46)和心力衰竭(OR 7.81,95%CI 2.56-23.8)呈正相关,与心肌梗死无显著关联(OR 1.17,95%CI 0.78-1.75);在女性中关联不明显。验证研究中,基因预测睾酮与心肌梗死呈正相关(OR 1.37,95%CI 1.03-1.82)。作者认为内源性睾酮可能是血栓栓塞和心力衰竭的可改变危险因素。

要点

  • 在男性中,由 JMJD1C 基因区域变异基因预测的内源性睾酮每升高 1 个单位(对数转换 nmol/L),血栓栓塞的 OR 为 2.09(95%CI 1.27-3.46)。
  • 在男性中,基因预测睾酮与心力衰竭呈正相关,OR 为 7.81(95%CI 2.56-23.8)。
  • 在男性中,基因预测睾酮与心肌梗死无显著关联,OR 为 1.17(95%CI 0.78-1.75)。
  • 在验证研究中,由 JMJD1C 基因区域变异基因预测的睾酮与心肌梗死呈正相关,OR 为 1.37(95%CI 1.03-1.82)。
  • 由 SHBG 基因区域潜在多效性变异基因预测的睾酮与上述结局均无关联。

适用人群与场景

  • REDUCE 随机对照试验中 3225 名欧洲裔男性,年龄 50-75 岁。
  • UK Biobank 中 392038 名白种英国人,年龄 40-69 岁,男女均有。
  • CARDIoGRAMplusC4D 1000 Genomes 研究中 171875 名参与者,约 77% 为欧洲血统,用于验证。

研究设计与关键结果

  • 研究设计为两样本孟德尔随机化研究,使用受精时随机分配的遗传变异作为工具变量推断因果关系,作为补充的随机化证据。
  • UK Biobank 参与者中,13691 例发生血栓栓塞(男性 6208 例,女性 7483 例),1688 例发生心力衰竭(男性 1186 例,女性 502 例),12882 例发生心肌梗死(男性 10136 例,女性 2746 例)。
  • 在男性中,由 JMJD1C 基因区域变异基因预测的内源性睾酮与血栓栓塞呈正相关(对数转换睾酮每单位增加 OR 2.09,95%CI 1.27-3.46),与心力衰竭呈正相关(OR 7.81,95%CI 2.56-23.8),与心肌梗死无显著关联(OR 1.17,95%CI 0.78-1.75)。
  • 在女性中,上述关联不明显。
  • 在验证研究中,由 JMJD1C 基因区域变异基因预测的睾酮与心肌梗死呈正相关(OR 1.37,95%CI 1.03-1.82)。
  • 遗传变异与结局的关联中未观察到过度异质性;由 SHBG 基因区域潜在多效性变异基因预测的睾酮与结局均无关联。

证据类型、等级与局限

  • 证据类型:两样本孟德尔随机化研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为内源性睾酮可能是血栓栓塞和心力衰竭的可改变危险因素。
  • 作者指出内源性睾酮可通过现有治疗进行控制。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To determine whether endogenous testosterone has a causal role in thromboembolism, heart failure, and myocardial infarction.

DESIGN: Two sample mendelian randomisation study using genetic variants as instrumental variables, randomly allocated at conception, to infer causality as additional randomised evidence.

SETTING: Reduction by Dutasteride of Prostate Cancer Events (REDUCE) randomised controlled trial, UK Biobank, and CARDIoGRAMplusC4D 1000 Genomes based genome wide association study.

PARTICIPANTS: 3225 men of European ancestry aged 50-75 in REDUCE; 392 038 white British men and women aged 40-69 from the UK Biobank; and 171 875 participants of about 77% European descent, from CARDIoGRAMplusC4D 1000 Genomes based study for validation.

MAIN OUTCOME MEASURES: Thromboembolism, heart failure, and myocardial infarction based on self reports, hospital episodes, and death.

RESULTS: Of the UK Biobank participants, 13 691 had thromboembolism (6208 men, 7483 women), 1688 had heart failure (1186, 502), and 12 882 had myocardial infarction (10 136, 2746). In men, endogenous testosterone genetically predicted by variants in the JMJD1C gene region was positively associated with thromboembolism (odds ratio per unit increase in log transformed testosterone (nmol/L) 2.09, 95% confidence interval 1.27 to 3.46) and heart failure (7.81, 2.56 to 23.8), but not myocardial infarction (1.17, 0.78 to 1.75). Associations were less obvious in women. In the validation study, genetically predicted testosterone (based on JMJD1C gene region variants) was positively associated with myocardial infarction (1.37, 1.03 to 1.82). No excess heterogeneity was observed among genetic variants in their associations with the outcomes. However, testosterone genetically predicted by potentially pleiotropic variants in the SHBG gene region had no association with the outcomes.

CONCLUSIONS: Endogenous testosterone was positively associated with thromboembolism, heart failure, and myocardial infarction in men. Rates of these conditions are higher in men than women. Endogenous testosterone can be controlled with existing treatments and could be a modifiable risk factor for thromboembolism and heart failure.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Luo S, Au Yeung SL, Zhao JV, et al. Association of genetically predicted testosterone with thromboembolism, heart failure, and myocardial infarction: mendelian randomisation study in UK Biobank. BMJ. 2019. PMID: 30842065. doi:10.1136/bmj.l476

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。